---
figid: PMC10705753__cancers-15-05536-g001
figtitle: Illustration of semaphorin 6A–D signaling pathways and their interaction
  with the cellular molecular network in cancer cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10705753
filename: cancers-15-05536-g001.jpg
figlink: /pmc/articles/PMC10705753/figure/F1
number: F1
caption: 'Illustration of semaphorin 6A–D signaling pathways and their interaction
  with the cellular molecular network in cancer cells. Activation of semaphorin signaling
  either via the “forward” (via plexins) or “reverse” mode by engaging RTK signaling
  is often associated with enhanced tumor angiogenesis, metastasis, and resistance
  to anticancer therapy. Pharmacological intervention (clofibrate, troglitazone, retinoic
  acid (RA)), molecular downregulation of SEMA6 activity (by dominant negative SEMA6A-1
  soluble extracellular domain, SEMA-ECD), downregulation of protein expression (miRNA),
  or even upregulation of SEMA6 expression (SEMA6C) may be beneficial as adjuvants
  along with anticancer therapeutics. VEGF: vascular endothelial growth factor; VEGFR1/2:
  vascular endothelial growth factor receptor 1/2; Src: Src kinase; FAK: focal adhesion
  kinase; ERK: extracellular signal-regulated kinase; RhoA: transforming protein RhoA;
  YAP: Yes-associated protein; PI3K: phosphoinositide 3-kinase; AKT: protein kinase
  B; MAPK: mitogen-activated protein kinase; NfkB: nuclear factor kappa-light-chain-enhancer
  of activated B cells; NOTCH1: neurogenic locus notch homolog protein 1; HES1: transcription
  factor HES1; FGFR1: fibroblast growth factor receptor 1; PPARα: peroxisome proliferator-activated
  receptor α; PPARγ: peroxisome proliferator-activated receptor γ; RXR: retinoid X
  receptor; GSK3: glycogen synthase kinase 3; Wnt: Wnt signaling pathway; STAT3: signal
  transducer and activator of transcription 3; EMT: epithelial to mesenchymal transition'
papertitle: Semaphorin 6 Family—An Important Yet Overlooked Group of Signaling Proteins
  Involved in Cancerogenesis
reftext: Wiktor Wagner, et al. Cancers (Basel). 2023 Dec;15(23).
year: '2023'
doi: 10.3390/cancers15235536
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: SEMA6 | plexins | RTKs | VEGF | VEGFR1/2 | tumor | dendritic cells | therapy
  prognosis
automl_pathway: 0.9257792
figid_alias: PMC10705753__F1
figtype: Figure
redirect_from: /figures/PMC10705753__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10705753__cancers-15-05536-g001.html
  '@type': Dataset
  description: 'Illustration of semaphorin 6A–D signaling pathways and their interaction
    with the cellular molecular network in cancer cells. Activation of semaphorin
    signaling either via the “forward” (via plexins) or “reverse” mode by engaging
    RTK signaling is often associated with enhanced tumor angiogenesis, metastasis,
    and resistance to anticancer therapy. Pharmacological intervention (clofibrate,
    troglitazone, retinoic acid (RA)), molecular downregulation of SEMA6 activity
    (by dominant negative SEMA6A-1 soluble extracellular domain, SEMA-ECD), downregulation
    of protein expression (miRNA), or even upregulation of SEMA6 expression (SEMA6C)
    may be beneficial as adjuvants along with anticancer therapeutics. VEGF: vascular
    endothelial growth factor; VEGFR1/2: vascular endothelial growth factor receptor
    1/2; Src: Src kinase; FAK: focal adhesion kinase; ERK: extracellular signal-regulated
    kinase; RhoA: transforming protein RhoA; YAP: Yes-associated protein; PI3K: phosphoinositide
    3-kinase; AKT: protein kinase B; MAPK: mitogen-activated protein kinase; NfkB:
    nuclear factor kappa-light-chain-enhancer of activated B cells; NOTCH1: neurogenic
    locus notch homolog protein 1; HES1: transcription factor HES1; FGFR1: fibroblast
    growth factor receptor 1; PPARα: peroxisome proliferator-activated receptor α;
    PPARγ: peroxisome proliferator-activated receptor γ; RXR: retinoid X receptor;
    GSK3: glycogen synthase kinase 3; Wnt: Wnt signaling pathway; STAT3: signal transducer
    and activator of transcription 3; EMT: epithelial to mesenchymal transition'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ECD
  - SEM1
  - SEMA6A
  - GPR162
  - SEMA6B
  - IGBP1
  - SEMA6C
  - PLXNA1
  - SEMA6D
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - PPARA
  - TCF4
  - TCF7L2
  - SNAI2
  - SRC
  - FGR
  - FYN
  - YES1
  - RHOA
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - STAT3
  - ZEB2
  - NOTCH1
  - FGFR1
  - ZEB1
  - HES1
  - GATD3
  - RXRA
  - RXRB
  - RXRG
  - GSK3A
  - GSK3B
  - GNG11
  - PTK2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - YAP1
  - CTNNB1
  - EPHB2
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - CCND1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - ITK
  - SLC22A3
  - SEMA3B
  - Clofibrate
  - Troglitazone
  - Thyroid
  - carcinoma
  - Melanoma
  - Glioblastoma
  - adenocarcinoma
  - cancer
  - Osteosarcoma
  - Pancreatic cancer
  - Colorectal cancer
  - Breast cancer
  - Renal cell carcinoma
---
